We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-4.03%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$22M
Cap. Flow
+$44.8M
Cap. Flow %
14.59%
Top 10 Hldgs %
56.38%
Holding
71
New
21
Increased
13
Reduced
13
Closed
22

Top Buys

Rank Stock Value
1
TAK icon
Takeda Pharmaceutical
TAK
+$15.3M
2
LH icon
Labcorp
LH
+$14.9M
3
CTLT
CATALENT, INC.
CTLT
+$13.9M
4
LLY icon
Eli Lilly
LLY
+$12.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.5M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$15.6M
2
AVTR icon
Avantor
AVTR
+$10M
3
HOLX
Hologic
HOLX
+$8.85M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$5.82M
5
CNC icon
Centene
CNC
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.14%
2 Real Estate 4.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
51
Boston Scientific
BSX
$71.4B
– –
-418,165
Closed -$15.6M
CNC icon
52
Centene
CNC
$32.4B
– –
-68,305
Closed -$5.78M
COR icon
53
Cencora
COR
$61.1B
– –
-11,515
Closed -$1.63M
DXCM icon
54
DexCom
DXCM
$32B
– –
-26,046
Closed -$1.94M
FATE icon
55
Fate Therapeutics
FATE
$325M
– –
-71,640
Closed -$1.77M
HOLX
56
DELISTED
Hologic
HOLX
– –
-127,656
Closed -$8.85M
IMUX icon
57
Immunic
IMUX
$205M
– –
-3,059
Closed -$106K
INCY icon
58
Incyte
INCY
$24.4B
– –
-31,211
Closed -$2.37M
NBIX icon
59
Neurocrine Biosciences
NBIX
$16.7B
– –
-27,992
Closed -$2.73M
PRAX icon
60
Praxis Precision Medicines
PRAX
$9.94B
– –
-5,273
Closed -$194K
QQQ icon
61
PUT
Invesco QQQ Trust
QQQ
$483B
– –
-13,300
Closed -$3.73M
SIBN icon
62
SI-BONE Inc
SIBN
$829M
– –
-430,159
Closed -$5.68M
SPY icon
63
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$822B
– –
-25,900
Closed -$9.77M
XBI icon
64
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-126,000
Closed -$9.36M
XBI icon
65
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-31,349
Closed -$2.33M
ZBH icon
66
Zimmer Biomet
ZBH
$18.4B
– –
-9,949
Closed -$1.04M
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-32,871
Closed -$5.82M
GBT
68
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-81,007
Closed -$2.59M
HZNP
69
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-8,454
Closed -$674K
1 2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Endurant Capital Management held 71 positions worth $307M, up 7.7% from $285M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Endurant Capital Management deployed $44.8M of net new capital in Q3 2022, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Avantor, an estimated $10M trimmed.

  • Endurant Capital Management's largest Q3 2022 buy was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.
  • Endurant Capital Management added most to Labcorp in Q3 2022, an estimated $14.9M increase.
  • Endurant Capital Management's biggest Q3 2022 reduction was Avantor, cutting an estimated $10M.
  • Endurant Capital Management fully exited Boston Scientific in Q3 2022, selling an estimated $15.6M.
  • Endurant Capital Management's ten largest holdings make up 56% of its $307M portfolio in Q3 2022.
  • Endurant Capital Management opened 21 new positions and closed 22 in Q3 2022.
  • Endurant Capital Management's portfolio value rose 7.7% quarter-over-quarter to $307M.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.